神经源性逼尿肌过度活动患者首次A型肉毒毒素治疗有效者长期重复治疗持续获益
这项事后分析纳入仅接受200 U onabotulinumtoxinA治疗的神经源性逼尿肌过度活动患者,按首次治疗后第6周尿失禁(UI)发作减少百分比分为<50%、50-74%、75-100%三组,评估后续重复治疗的UI减少、生活质量及不良事件。结果显示首次治疗≥50%UI减少者后续治疗疗效持续,而<50%者后续治疗也可改善,提示不应因首次低反应而放弃再次治疗。
要点
- 83.1%(162/195)的患者首次onabotulinumtoxinA治疗后UI减少≥50%。
- 首次治疗UI减少50-74%和75-100%组后续治疗2-6次UI减少百分比保持稳定。
- 首次治疗UI减少<50%组后续治疗UI减少百分比和≥50%减少比例均升高。
核心结论
- 首次onabotulinumtoxinA治疗后UI减少≥50%的NDO患者在后续治疗中持续获得UI和生活质量改善,持续4年。
- 首次治疗UI减少<50%不一定预测后续治疗低反应。
- 作者认为应在判定患者不适合onabotulinumtoxinA治疗前至少尝试第二次治疗。
研究设计与样本
- 事后分析,纳入3年扩展研究(继52周III期研究后)中仅接受200 U onabotulinumtoxinA按需治疗、符合预设再治疗标准的NDO患者。
- 按首次治疗后第6周UI发作较基线平均减少百分比分层:<50%组(第1组,n=33)、50-74%组(第2组,n=23)、75-100%组(第3组,n=139)。
主要发现
- 83.1%(162/195)的患者首次onabotulinumtoxinA治疗后UI减少≥50%。
- 第2组后续治疗2-6次UI平均减少百分比范围为64.5-83.5%,第3组为79.4-88.0%,低反应组为36.3-60.3%。
- 第2组后续治疗2-6次达到≥50%UI减少的比例范围为75.0-100%,第3组为87.3-97.1%,低反应组为48.3-72.7%。
- 即使首次治疗低反应,37.9%的患者在所有后续治疗中达到≥50%UI减少。
- 第2组和第3组I-QOL评分改善持续为MID的2-3倍;低反应组至少50%的患者在治疗2-6次达到或超过MID。
关键数值与推荐
- UI减少百分比分层阈值:<50%、50-74%、75-100%。
- I-QOL最小重要差异(MID)为+11分。
临床怎么用
- 作者认为,首次onabotulinumtoxinA治疗后UI减少<50%不应视为后续治疗低反应的预测因素。
- 作者强调在判定患者不适合onabotulinumtoxinA治疗前应至少尝试第二次治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether response to first treatment with onabotulinumtoxinA is predictive of long-term treatment outcome in patients with neurogenic detrusor overactivity (NDO). PATIENTS AND METHODS: Patients with NDO who were enrolled in a 3-year extension study (after a 52-week phase III study) received onabotulinumtoxinA 'as needed', based on fulfilment of prespecified retreatment criteria. This post hoc analysis included patients who received only the 200-U dose during the phase III and extension studies. Data on mean percent reduction from baseline in urinary incontinence (UI) episodes at week 6 after the first treatment were analysed, and the patients were stratified into three response groups: <50% (group 1; n = 33), 50-74% (group 2; n = 23), and 75-100% (group 3; n = 139). The following were assessed: change from baseline in mean percent UI reduction; proportions of patients who achieved ≥50% and 100% UI reduction after each subsequent treatment, and patients who achieved ≥50% UI reduction after all subsequent treatments; change from baseline in Incontinence Quality of Life (I-QOL) total summary score; and the proportion of patients who achieved or exceeded the minimally important difference (MID; +11 points) in I-QOL score. Adverse events (AEs) were also assessed. RESULTS: The majority of the patients (83.1%; 162/195) experienced a ≥50% UI reduction after onabotulinumtoxinA treatment 1. Baseline characteristics were largely similar across the groups. After treatment 1, the mean percent reduction in UI remained consistent in subsequent treatments 2-6 for patients in response group 2 (range: 64.5-83.5%) and group 3 (range: 79.4-88.0%), but increased for those in the low response group (range: 36.3-60.3%). After treatment 1, the proportion of patients who achieved ≥50% reduction in UI episodes was consistent with subsequent treatments 2-6 in group 2 (range: 75.0-100%) and group 3 (range: 87.3-97.1%), but increased in the low response group (range: 48.3-72.7%). Even among those who achieved a low response after treatment 1, 37.9% of patients achieved ≥50% UI reduction in all subsequent treatments. Improvements in I-QOL scores in groups 2 and 3 were consistently 2-3 times the MID. In the low response group, at least 50% of the patients achieved or exceeded the MID with treatments 2-6. AEs were similar across all response groups and consistent across repeated treatments. CONCLUSION: Patients with NDO with a ≥50% UI reduction after their first onabotulinumtoxinA treatment continued to experience consistent improvements in UI and quality of life with subsequent treatments over the duration of 4 years. A <50% UI reduction after first treatment did not necessarily predict low response with subsequent treatments. Thus, these results underscore the importance of attempting at least a second treatment with onabotulinumtoxinA before deeming patients unsuitable for onabotulinumtoxinA therapy.
引用
- Denys P, Dmochowski R, Aliotta P, et al. Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity. BJU Int. 2017. PMID: 28139068. doi:10.1111/bju.13795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。